IP Library Granted Patent US 9,795,706
Granted Patent B2
US 9,795,706 · App. 15/089,694 · Granted Oct 24, 2017

Silicone scar treatment preparation

Inventor: Paul Guilbaud (Largo, FL)
Assignee: Advanced Bio-Technologies, Inc.
A61L26/0019A61K8/25A61K8/345A61K8/35A61K8/37A61K8/40A61K8/4973A61K8/585A61K8/891A61K8/895A61K31/12A61K31/216A61K31/573A61K31/618A61K47/02A61K47/22A61K47/24A61K47/34A61L26/0004A61L26/008A61L26/0052A61L26/0066A61L26/0095A61Q17/04A61K9/0014A61K2800/592A61K2800/594A61K2800/95A61L2300/41A61L2430/34Y10S514/871Y10S514/928
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,795,706
App. No.
15/089,694
Granted
Oct 24, 2017
Kind
B2
Abstract

Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.

Claims (32)

1. A composition for topical application, the composition consisting essentially of:

(a) a volatile component having a cyclic siloxane and being present in the composition at a concentration ranging from 12 wt % to 45 wt % of the overall composition;

(b) siloxane matrix precursors at a concentration ranging from 25 wt % to 60 wt % of the overall composition that are capable of polymerization during topical application to form a siloxane matrix;

(c) an active component solubilized in the composition; and

(d) a volatile coagent being present in the composition at a concentration ranging from 5 wt % to 50 wt % of the overall composition and including at least one selected from the group consisting of dimethyl isosorbide, pentylene glycol, and isopropyl myristate, wherein:

the active component is a corticosteroid ranging from 0.5 wt % to 3 wt %.

2. The composition of claim 1 , wherein the volatile component comprises cyclopentasiloxane.

3. The composition of claim 1 , wherein the silioxane matrix precursors comprise dimethicone and dimethicone crosspolymer.

4. The composition of claim 1 , wherein the siloxane matrix precursors comprise dimethicone crosspolymer and fumed silica.

5. The composition of claim 1 , wherein the siloxane matrix precursors comprise dimethicone, dimethicone crosspolymer, and fumed silica.

6. The composition of claim 5 , wherein the corticosteroid is hydrocortisone or a salt thereof at a concentration ranging from 0.5 wt % to 3 wt % of the overall composition.

7. The composition of claim 6 , wherein the volatile coagent comprises 10 wt % to 25 wt % of the overall composition.

8. The composition of claim 7 , wherein the volatile component is cyclopentasiloxane.

9. The composition of claim 1 , wherein the corticosteroid is hydrocortisone or a salt thereof at a concentration ranging from 0.5 wt % to 1 wt % of the overall composition.

10. The composition of claim 9 , wherein the volatile coagent comprises 10 wt % to 25 wt % of the overall composition.

11. The composition of claim 10 , wherein the volatile component is cyclopentasiloxane.

12. A composition for topical application, the composition consisting essentially of:

(a) a volatile component having a cyclic siloxane and being present in the composition at a concentration ranging from 12 wt % to 45 wt % of the overall composition;

(b) siloxane matrix precursors at a concentration ranging from 25 wt % to 60 wt % of the overall composition that are capable of polymerization during topical application to form a siloxane matrix;

(c) an active component solubilized in the composition; and

(d) a volatile coagent being present in the composition at a concentration ranging from 5 wt % to 50 wt % of the overall composition and including at least one selected from the group consisting of dimethyl isosorbide, pentylene glycol, and isopropyl myristate, wherein:

the active component includes an agent having sun screening activity.

13. The composition of claim 12 , wherein the agent having sun screening activity comprises octinoxate and octisalate.

14. The composition of claim 13 , wherein the agent having sun screening activity further comprises at least one of octocrylene and oxybenzone.

15. The composition of claim 14 , wherein the agent having sun screening activity further comprises octocrylene and oxybenzone.

16. The composition of claim 12 , wherein the volatile component comprises cyclopentasiloxane.

17. The composition of claim 12 , wherein the silioxane matrix precursors comprise dimethicone and dimethicone crosspolymer.

18. The composition of claim 12 , wherein the siloxane matrix precursors comprise dimethicone crosspolymer and fumed silica.

19. The composition of claim 12 , wherein the siloxane matrix precursors comprise dimethicone, dimethicone crosspolymer, and fumed silica.

20. The composition of claim 19 , wherein the agent having sun screening activity comprises octinoxate and octisalate.

21. The composition of claim 20 , wherein the volatile coagent comprises 10 wt % to 25 wt % of the overall composition.

22. The composition of claim 21 , wherein the volatile component is cyclopentasiloxane.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2026
From: GUILBAUD, PAUL
To: ADVANCED BIO-TECHNOLOGIES, INC.
Reel/Frame 074740/0577 →
Continuity (4)
Continuation 14322584 · Jul 2, 2014
Continuation 13548899 · Jul 13, 2012
Continuation 12487489 · Jun 18, 2009
Related Publication 20160213810A1 · Jul 28, 2016